Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
BackgroundHemophagocytic lymphohistiocytosis (HLH) is a severe disorder characterized by excessive secretion of cytokines. Even with the recommended HLH-94/2004 regimen, over 30% of patients remain refractory to frontline therapy or relapse after an initial response, leading to poor clinical outcome...
Сохранить в:
| Главные авторы: | , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2023-06-01
|
| Серии: | Frontiers in Immunology |
| Предметы: | |
| Online-ссылка: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1211655/full |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|